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ABSTRACT 
 
Infectious laryngotracheitis virus (ILTV) causes respiratory distress, decreased 
egg production, conjunctivitis, and death in chickens.  ILT can be prevented by 
vaccination.  Traditionally, that vaccination is with a chicken embryo origin (CEO) 
vaccine.  However, CEO vaccines can revert to virulent ILTV and cause outbreaks.  One 
of the successes of the recombinant vaccines with gene inserts for ILT is that they do not 
revert to virulence, but do prevent ILT symptoms.  However, these same recombinant 
vaccines do not necessarily prevent replication of ILTV in the trachea of chickens, which 
then can lead to ILT outbreaks. 
One of the regulations for ILT vaccines is that they must protect chickens against 
inoculation with an ILT challenge virus. All licensed vaccines in the U.S. are licensed by 
the United States Department of Agriculture’s (USDA) Center for Veterinary Biologics 
(CVB).  The CVB provides ILT challenge virus to biologics companies for efficacy 
testing of vaccines.  The current USDA challenge virus strain was generated through egg 
passage from a 1960s strain of ILTV.  Recently, the CVB was able to acquire an ILT 
field isolate from an outbreak in a laying hen flock that had been vaccinated with a 
recombinant ILT vaccine. 
Mortality, clinical signs and pathogenicity of this field isolate were compared to 
the current USDA challenge virus.  An interesting aspect of the research was that several 
asymptomatic chickens still had tracheal lesions, both from the field isolate and current 
challenge virus, indicating viral replication without clinical signs.  This is not entirely 
surprising due to research indicating similar results with some recombinant ILT vaccines, 
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but it does reinforce that prevention of symptoms does not equal prevention of viral 
replication. 
The ILT field isolate produced clinical signs and tracheal lesions similar to the 
USDA challenge virus, and the field isolate was able to cause symptoms at a lower 
infectious douse then the USDA challenge virus to achieve the same results.  These 
results indicate that the ILT field isolate is a viable candidate for use in vaccination 
challenge studies.  Future work will need to be undertaken to perform genetic analysis of 
the ILT field strain isolated by the USDA and other field strains to determine genetic 
relationship to vaccine strains. 
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CHAPTER 1. INFECTIOUS LARYNGOTRACHEITIS AND VACCINATION 
 
 
Abstract 
  
 Infectious laryngotracheitis virus (ILTV) causes respiratory distress, reduction in 
egg production, conjunctivitis, and death in chickens. Severe cases of infectious 
laryngotracheitis (ILT) can have morbidity of 100% and mortality rates as high as 70%, 
with the average percentage for mortality ranging from 10-20%. In mild cases, morbidity 
can be as low as 5% and mortality can be as low as 0.1%. In the United States, 
vaccination for ILT is predominately performed using one of the types of vaccines: chick 
embryo origin (CEO), tissue culture origin (TCO) and recombinant vaccines. 
 It is critical that traditional live attenuated ILT vaccines prevent disease by 
preventing infection by wild type strains.  However, these vaccines can revert to 
virulence and cause outbreak situations.  The recombinant vaccines prevent disease and 
do not revert to virulence, but they may allow wild type strains to infect and replicate in 
birds, which can also lead to outbreaks. 
 The importance of not only preventing disease, but also infection, has become 
more apparent as the understanding of the immunological response to ILTV and ILT 
vaccines has increased.  Current research into different vaccination methods, new vectors 
for recombinant vaccines, and eliciting a cell mediated immune response in the trachea 
has moved ILT vaccination towards preventing infection. 
 ILT prevention is a complex challenge. This literature review will give an 
overview of the ILT virus, advantages and disadvantages associated with currently 
license vaccines in the U.S, and recent research to improve vaccination for ILT. 
1. Introduction 
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Infectious laryngotracheitis virus (ILTV) causes respiratory distress, reduction in 
egg production, conjunctivitis, and death in chickens (1).  It is an alphaherpesvirus that 
can cause both severe and mild disease (1-3).  Severe cases of infectious laryngotracheitis 
(ILT) can have morbidity of 100% and mortality rates as high as 70%, with the average 
percentage for mortality ranging from 10-20% (3).  In mild cases, morbidity can be as 
low as 5% and mortality can be as low as 0.1% (3).  Clinical manifestations in mild forms 
include conjunctivitis, whereas more severe forms may include birds coughing blood 
from tracheal epithelial cell hemorrhage (3, 4).  
  In the United States, vaccination for ILT is predominately performed using one 
of the types of vaccines: chick embryo origin (CEO), tissue culture origin (TCO) and 
recombinant vaccines (3).  This literature review will give an overview of the ILT virus, 
advantages and disadvantages associated with currently license vaccines in the U.S, and 
recent research to improve vaccination for ILT. 
2.  Infectious Laryngotracheitis Virus 
 
 2.1. Strain similarities and differences. Discerning differences in ILTV strains has 
traditionally been performed using restriction fragment length polymorphism (RFLP) 
analysis.  The RFLP analysis divides ILTV strains into different classes based on genetic 
markers of ILTV, including genes for ICP4, glycoprotein G, glycoprotein M, and 
thymidine kinase (5-10).  Current research has also focused on full genome sequencing to 
discern strain differences (9, 10). 
Data from both RFLP and sequencing indicates that ILTV strains are genetically 
similar.  However, there are distinct differences between American-European strains and 
Australian strains (8-10).  The Serva strain of ILTV is predominately found in vaccines 
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and has been genetically linked to outbreak strains in Europe and the Americas.  The SA2 
and A20 strains are predominately found in vaccines and outbreak strains in Australia.  
This difference in strains by continent has led to variations in RFLP class designation 
between the American and Australian ILTV strains (6-8, 10). 
Although ILTV strains are genetically similar, small genetic differences in 
herpesviruses can cause dramatic changes in clinical symptoms.  The SA2 and A20 
strains are 99.9% genetically identical.  The SA2 strain is a CEO vaccine in Australia.  
To reduce the virulence of the SA2 strain, the virus was passed in chicken cells.  The 
TCO vaccine that was produced was designated the A20 strain.  Based on full genomic 
sequencing, SA2 and A20 have two single nucleotide polymorphisms (SNP) that are 
nonsynonymous, one in ORF B and one in UL15 genes.  Amino acid changes in these 
two genes appear to cause a decrease in cell to cell spread in the A20 strain, and in the 
process, decrease the virulence of the virus (9).  
The importance of the genetic differences between the continental strains was not 
fully realized until a European vaccine for ILTV was introduced into Australia.  Flocks in 
the same geographical area were vaccinated with the standard Australian strain A20 and 
the European Serva vaccine strain (8, 11).  Following a disease outbreak in this area, two 
new strains of ILTV were isolated.  Based on RFLP analysis, sequencing and 
phylogenetic analysis, the recovered strains were genetically very similar and were a 
result of recombination events of the European and Australian vaccine strains.  An 
example of one of the recombination events is that the ICP4 sequence of the Australian 
strain was replaced with the ICP4 from the American strain (8, 10, 11).   
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Although this is the first time a significant recombination event was documented 
causing an outbreak of ITLV, it has happened before (10).  Based on phylogenetic 
analysis outbreaks in production facilities can often be traced back to vaccine strains, 
however outbreaks in backyard flocks can be caused by virus that is genetically different 
than vaccine strains.  These backyard flock strains have genetic components that are 
similar to vaccine strains, but also have elements that are different, indicating that 
recombination of ILTV may happen more often than first thought (10). 
2.2. Serological detection. Serologically, all ILTV strains are similar because 
antiserum produced from one strain can neutralize another.  Detection of antibodies to 
ILTV in chickens is performed using enzyme linked immunosorbent assays (ELISAs) 
(3).  There are currently two licensed diagnostic test kits for ILTV antibody detection 
from Zoetis (Synbiotics) and Biochek (12). 
  ELISA assays have also been shown to be as sensitive as other serological tests, 
including virus neutralization, agar gel immunoprecipitation and indirect 
immunofluorescence assays (13).  It is also an assay that can be automated for high 
throughput analysis (3).  ELISAs using monoclonal antibodies to specific glycoproteins 
could be valuable in differentiating birds vaccinated with recombinant vaccines from 
those either vaccinated with CEO or TCO vaccines or infected with a field strain virus 
(14).   
3.  ILT vaccination 
  
 3.1. CEO vaccines. CEO vaccines are live viruses that have been attenuated by 
repeated passage in embryonated chicken eggs (3).  These vaccines, ideally, do not 
produce disease, but do cause infection in the trachea, and elicit an immune response 
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(15).  Onset of immunity can occur a few days after vaccination, with duration of 
immunity lasting fifteen to twenty weeks after vaccination, although it can last up to a 
year (3).   
A problem with CEO vaccines is reversion to virulence (14, 16).  Herpesviruses 
are known to become latent and then reactivate, usually due to an environmental stress (3, 
16).  CEO vaccines, although attenuated, are live herpesviruses and can become latent.  
Certain stressors, like moving chickens to new housing or the start of lay, can cause 
reactivation of latent ILT virus (17).  This reactivation can lead to shedding of the virus, 
and cause horizontal transmission to naïve chickens (14, 18, 19).  Once infected, naïve 
chickens can become symptomatic, leading to an ILT outbreak.   
Increased virulence, including mortality, morbidity and tracheal lesions, can occur 
after one passage of CEO vaccine through a chicken, although morbidity, mortality and 
tracheal lesions increase considerably after 10 to 20 passages in chickens (16).   Due to 
this reversion to virulence, some states require approval before use of the CEO vaccines 
for vaccination (20).  Approval in Texas is intended to control a confirmed outbreak 
where all birds to be vaccinated are known to have already been exposed to the virus 
(20). 
 3.2. TCO vaccines. TCO vaccines are produced in cell culture to attenuate the 
virus.  On chicken passage studies, increases in morbidity, mortality or lesion scores that 
were observed for the CEO vaccines, were not noticed in the TCO vaccines (16).  
According to these same studies, there was a moderate increase in morbidity at chicken 
passage 20, but no increase in death or lesion scores (16).  TCO vaccines do have a 
decreased duration of immunity when compared to CEO vaccines (3). ILTV growth in 
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cell culture does not require certain genes that are needed for in-vivo replication, 
including genes in open reading frames (ORFs) A to E (21).  This may be why TCO 
vaccines have a reduced risk of reversion to virulence. 
3.3. Administration of CEO and TCO vaccines. CEO and TCO vaccines are 
administered via drinking water and coarse spray (4, 22-24).  They can also be given via 
infraorbital sinus inoculation (22, 24).  Administration of CEO and TCO vaccines occurs 
mainly in layer or breeder type chickens.  Vaccination is not recommended for broiler 
type chickens unless other birds in the flock are vaccinated or there is an outbreak (22, 
24).  ILTV vaccination is expensive to implement for broilers and vaccination can cause 
reduced performance (22).  In broiler production systems, biosecurity is seen as the main 
form of prevention for ILT outbreaks (22, 24). 
For layer or breeder production systems, CEO and TCO vaccines are administered 
at 6 to 8 weeks of age, and then again at 12 to 15 weeks (24).  The greatest protection 
occurs from 15-20 weeks, and protection immunity may vary over the year (3). The 
effectiveness of revaccination in boosting immunity is unknown (3).     
 3.4. Recombinant vaccines. Another option for ILT vaccination is recombinant 
vaccines.  Licensed recombinant vaccines do not revert to virulence like the CEO 
vaccines since they only contain one or two gene inserts from ILTV that are inserted into 
herpes virus of turkeys (HVT) or fowl pox vector (3, 14, 15, 25, 26).  Vaccination can 
occur early by in ovo vaccination or at 1 day of age by subcutaneous vaccination.  In ovo 
vaccination provides protection at a very young age, unlike the traditional live attenuated 
vaccines, where vaccination may not occur until 6 weeks of age (14, 26).   
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The recombinant vaccines depend on the immunogenicity of herpesvirus 
glycoproteins.  The main glycoproteins used in research are glycoproteins B, C, D G and 
I (2, 15, 27-32).  Currently licensed vaccines contain glycoproteins B, D or I, or a 
combination of these glycoproteins (25).  The importance of expression of glycoproteins 
for ILT disease prevention is discussed more in depth later in this paper.  
4.  Recombinant vaccine regulation in the United States 
 
As of January 2015, 31 poultry products licensed in the US included a 
recombinant agent (12).  In the early 1990s, the first poultry recombinant vaccine was 
licensed.  It used fowl pox as a vector for a Newcastle Disease Virus (NDV) gene insert 
(33).  Shortly after, a fowl pox-ILTV recombinant vaccine was licensed.  This vaccine is 
produced by Ceva Biomune.  There are also HVT-ILTV recombinant vaccines from two 
separate manufacturers, Ceva Biomune and Merck (12).  
The USDA’s Center for Veterinary Biologics (CVB) licenses all animal vaccines 
in the United States, including recombinant vaccines.  The CVB was created to enforce 
the Virus Serum Toxin Act and regulations for vaccine licensing and testing are detailed 
in part 9 of the Code of Federal Regulations (9CFR).  These regulations include testing 
requirements for purity, potency, efficacy and safety for both killed and live standard 
type vaccines (34-36).   
Licensure of recombinant vaccines entails complexities that the original creators 
of the 9CFR could not have anticipated.  Some of those include: stability of the gene 
insert or inserts; safety of a genetically modified live product in the field; production of 
recombinant antigenic protein; and purity of the genetic sequences of both the vector and 
the inserts (35).   
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General guidelines for licensure of biologics products using new biotechnology 
were issued in USDA Veterinary Services (VS) Memorandum 800.68 in 1984 (37).  
These basic guidelines were an attempt to reconcile the USDA requirements with 
National Institutes of Health standards on biotechnology research.  After the release of 
the first recombinant vaccine for pseudorabies, there was concern from the public about 
the safety of live genetically modified vaccine organisms being released into the 
environment and mixing with wild type organisms.  In response to that concern, the 
USDA outlined new procedures incorporating the National Environmental Policy Act and 
requiring environmental assessment of the impact of recombinant products (35).    
VS Memo 800.205 outlines the studies and testing required for varying categories 
of biotechnology derived veterinary products beyond typical 9CFR testing (38).  As 
outlined in VS Memo 800.205, testing may include recombination studies, shed and 
spread studies and sequencing of the construct, flanking regions of the insert, and the 
insert(s).  If a recombinant construct will be expressing an antigenic protein, this protein 
should be detectable by an in vitro assay (Western Blot, fluorescent antibody staining, 
etc.).  The memo creates three different categories of biological products: Category I are 
biotechnology derived products that are inactivated; Category II are gene deleted, live 
products; and Category III are live vector products with foreign gene insert(s).  The 
testing required for a recombinant product depends on the construct, what category of 
biological product, and a risk analysis performed by the CVB (38). 
For ILT recombinant vaccines, the vaccine has to perform to the same efficacy 
standards as the traditional ILT vaccines.  This efficacy standard is tied to a vaccination 
challenge study described in 9CFR 113.328 (39).  The vaccination challenge study 
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involves vaccinating 20 birds and then challenging them with a virulent ILT virus, which 
can be provided by the CVB.  The birds are monitored for ten days for ILT disease 
symptoms.  Protection is measured based on decrease of symptoms of the disease when 
compared to non-vaccinated, ILTV challenged control birds (39). 
5.  ILT recombinant vaccination problems 
  
Protection from ILT disease by vaccination with ILT recombinant vaccines 
depends on a humoral immune response and antibody production to the ILTV 
glycoprotein inserts. However, it was determined that ILTV immunity is driven by cell 
mediated immunity and not humoral immunity.  Bursectomized chickens inoculated with 
traditional CEO ILT vaccine were protected from ILT challenge virus infection (40).  
This indicates that antibodies to ILT do not play an integral role in preventing ILTV 
infection.   
More recently, studies have indicated that the live CEO vaccines produce an 
immune response that prevents viral replication upon challenge (14, 15, 25).  It appears 
that the initial T- cell response upon vaccination in the trachea is critical to prevent future 
replication of virus, specifically a T-helper cell response (15, 31, 41, 42).  The HVT-
ILTV and fowl pox-ILTV recombinant vaccines are not given by an oral-pharyngeal 
route.  The recombinant vaccines depend on the humoral immune response, not the cell 
mediated immune response of the trachea.  Antibodies can prevent symptoms of a field-
acquired ILT infection, but virus replication can continue, which can lead to viral latency.  
As mentioned previously, upon stress, the latent virus can be reactivated and disease 
outbreaks can occur. 
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6.  Future of ILT recombinant vaccines 
 
 6.1. Dual vaccination. Continued viral replication, leading to decreased efficacy, 
has also been reported for recombinant vaccines with Newcastle Disease Virus (NDV) 
inserts.  The solution that was found was to vaccinate with the recombinant NDV vaccine 
and boost with the live attenuated vaccine.  This produced better protection than using 
either vaccine alone (43, 44).  This same method may be useful for vaccinating for ILT, 
especially in relation to the TCO vaccines.  The immune system could be primed, using 
the recombinant vaccine, for vaccination using the lower virulence TCO vaccine.  Further 
research would have to be performed to determine if protection levels would be 
comparable to the NDV vaccination study. 
 6.2. Immune modulator and DNA vaccine. One of the ways for a recombinant ILT 
vaccine to induce a humoral immune response is by expression of an immune modulator 
protein.  Researchers have demonstrated this using a fowl pox vector expressing ILT 
glycoprotein B (gB) and interleukin-18 (IL-18) (41).  Glycoprotein B was chosen because 
it is known to be conserved among herpesviruses.  It also has been used in previous 
recombinant ILTV vaccines and has been shown to prevent disease.  IL-18 was chosen 
because it stimulates T-helper 1 cells to secrete interferon-γ (IFN-γ) (31, 41, 42).  IFN-γ 
has been shown to be an important signaling cytokine for preventing herpesvirus 
infection, clearing herpesvirus infection and preventing herpesvirus from reactivating 
from latency (45-48). 
The fowl pox-gB-IL-18 (rFPV-gB/IL-18) vaccine increased CD4 to CD8 T- cell 
ratios significantly in comparison to vaccination with recombinant fowl pox containing 
only a glycoprotein B insert (rFPV-gB).  After challenge, morbidity and mortality were 
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0% for the rFPV-gB/IL-18 vaccine, which was significantly less than for that of the 
rFPV-gB or ILTV live attenuated vaccines.  Also, 0 out of 10 birds had detectable ILTV 
by PCR of tracheal tissue for the rFPV-gB/IL-18 vaccine, whereas 2/10 and 3/10 birds 
did for the rFPV-gB and ILTV live attenuated vaccines respectively.  The rFPV-gB/IL-18 
vaccine protected 100% of birds based on clinical signs, mortality and PCR of tracheal 
tissues (41). 
 An immune modulator can also be used with DNA vaccines.  DNA vaccines are 
naked DNA that are encoded with an immunogenic protein or proteins, that when 
inoculated into cells or an animal, produce the immunogen.  These vaccines do not 
involve injecting live virus and therefore there is no worry of reversion to virulence.   
A DNA vaccine containing genes for ILT gB and IL-18 caused significantly 
higher IFN-γ levels in peripheral blood mononuclear cells (PBMCs) of chickens than did 
a DNA vaccine expressing just the gB plasmid.  The gB/IL-18 DNA vaccine had both 
morbidity and detectable virus in the trachea; although the level was significantly lower 
than the DNA vaccine expressing just the gB plasmid.  The gB/IL-18 vaccine had an 80% 
protection rate based on clinical signs, mortality and PCR of tracheal tissue, but did 
require a booster vaccination 14 days after initial vaccination (31, 42).   
6.3. Other vectors. Another way to trigger the cell mediated immune response is 
to use a vector that has an inoculation route similar to ILTV.  NDV live attenuated 
vaccines are typically given by coarse spray or drinking water, similar to how ILTV live 
attenuated vaccines are administered.  Researchers at the Southeast Poultry Research 
Laboratory (SERPL) created two separate NDV LaSota strain recombinant vaccines, one 
with an ILTV glycoprotein B (gB) insert and the other with an ILTV glycoprotein D (gD) 
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insert.  The gB and gD vaccines were given at 1 day of age to specific pathogen free egg 
type chickens and the gB at 3 weeks of age to broiler type chickens (25).   
The NDV LaSota strain with either the gB or gD insert were as protective as 
traditional NDV vaccines against challenge with NDV.  When challenged with ILTV, the 
vaccinated birds from both groups were 90% protected against clinical symptoms, and 
the birds that did show clinical symptoms had very mild symptoms.  By a real time PCR 
assay, both vaccines decreased viral load in tears and tracheas, with the gB vaccine 
performing better.   The gB vaccine performed as well as the traditional CEO vaccine in 
broilers, although it did not decrease viral load in the tracheas as much as the live 
attenuated ILTV vaccines (25). 
7. Conclusion 
 
 Infectious laryngotracheitis is a major issue for the poultry industry.  As an 
example, a 1998 outbreak in the Delmarva peninsula in the Eastern United States cost 
producers over $1 million dollars, factoring in decreased production, mortality, 
vaccination and medication (4).  It is also a complex issue, since vaccination can be a 
major factor in outbreaks. 
It is critical that traditional live attenuated ILT vaccines prevent disease by 
preventing infection by wild type strains.  However, these vaccines can revert to 
virulence and cause outbreak situations.  The recombinant vaccines prevent disease and 
do not revert to virulence. 
Importantly, the focus of vaccination is largely on prevention of disease and not 
prevention of viral infection.   The USDA licensed recombinant vaccines for ILT protect 
against disease symptoms.  They meet all of the regulations for an ILT vaccine and meet 
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the regulations for recombinant vaccines.  However, they do not necessarily stop 
infection by wild type strains.  This can lead to wild type virus becoming latent and 
reactivating at a later time, which can cause outbreak situations. 
 The importance of not only preventing disease, but also infection, has become 
more apparent as the understanding of the immunological response to ILTV and ILT 
vaccines has increased (14, 15, 49).  For some viruses, preventing disease may be 
adequate, but for a herpesvirus like ILTV, that can become latent and reactivate at a later 
time point, preventing infection is also important. 
 The future of ILT vaccine research lies in finding a vaccine that does not revert to 
virulence, and can prevent viral replication upon challenge.  The solution may be in 
performing dual vaccinations with recombinant vaccine and modified live vaccines, 
expression of an immune modulator in a recombinant vaccine, or looking at different 
vectors for ILT gene inserts.  Due to the complexity of the problems and issues discussed 
here surrounding ILT vaccination; the solution will need to be a collaborative effort 
between poultry producers, researchers, vaccine regulators and vaccine manufacturers. 
 
References 
 
1. Dufour-Zavala, L. Epizootiology of infectious laryngotracheitis and presentation 
of an industry control program. Avian Diseases. 52:1-7. 2008. 
 
2. Fuchs, W., J. Veits, D. Helferich, H. Granzow, J.P. Teifke, and T.C. Mettenleiter. 
Molecular biology of avian infectious laryngotracheitis virus. Veterinary Research. 
38:261-279. 2007. 
 
3. Bagust, T.J., R.C. Jones, and J.S. Guy. Avian infectious laryngotracheitis. Off. 
Int. Epiz. 19:483-492. 2000. 
 
4. Infectious laryngotracheitis (ILT). Canadian Poultry Consultants Ltd. 
http://www.canadianpoultry.ca. June 16, 2015. 
 
14 
 
5. Kirkpatrick, N.C., A. Mahmoudian, D. O'Rourke, and A.H. Noormohammadi. 
Differentiation of infectious laryngotracheitis virus isolates by restriction fragment length 
polymorphic analysis of polymerase chain reaction products amplified from multiple 
genes. Avian Diseases. 50:28-34. 2006. 
 
6. Oldoni, I., and M. Garcia. Characterization of infectious laryngotracheitis virus 
isolates from the US by polymerase chain reaction and restriction fragment length 
polymorphism of multiple genome regions. Avian Pathology. 36:167-176. 2007. 
 
7. Oldoni, I., A. Rodriguez-Avila, S. Riblet, and M. Garcia. Characterization of 
infectious laryngotracheitis virus (ILTV) isolates from commercial poultry by 
polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP). 
Avian Diseases. 52:59-63. 2008. 
 
8. Blacker, H.P., N.C. Kirkpatrick, A. Rubite, D. O'Rourke, and A.H. 
Noormohammadi. Epidemiology of recent outbreaks of infectious laryngotracheitis in 
poultry in Australia. Australian Veterinary Journal. 89:89-94. 2011. 
 
9. Lee, S.W., J.M. Devlin, J.F. Markham, A.H. Noormohammadi, G.F. Browning, 
N.P. Ficorilli, C.A. Hartley, and P.F. Markham. Comparative analysis of the complete 
genome sequences of two Australian origin live attenuated vaccines of infectious 
laryngotracheitis virus. Vaccine. 29:9583-9587. 2011. 
 
10. Lee, S.W., J.M. Devlin, J.F. Markham, A.H. Noormohammadi, G.F. Browning, 
N.P. Ficorilli, C.A. Hartley, and P.F. Markham. Phylogenetic and molecular 
epidemiological studies reveal evidence of multiple past recombination events between 
infectious laryngotracheitis viruses. PloS One. 8:e55121. 2013. 
 
11. Lee, S.W., P.F. Markham, M.J. Coppo, A.R. Legione, J.F. Markham, A.H. 
Noormohammadi, G.F. Browning, N. Ficorilli, C.A. Hartley, and J.M. Devlin. Attenuated 
vaccines can recombine to form virulent field viruses. Science. 337:188. 2012. 
 
12. Veterinary Biological Products. USDA. Center for Veterinary Biologics, Ames, 
Iowa. 2015. 
 
13. Adair, B.M., D. Todd, E.R. McKillop, and K. Burns. Comparison of serological 
tests for detection of antibodies to infectious laryngotracheitis virus. Avian Pathology.  
14:461-469. 1985. 
 
14. Coppo, M.J., A.H. Noormohammadi, G.F. Browning, and J.M. Devlin. 
Challenges and recent advancements in infectious laryngotracheitis virus vaccines. Avian 
Pathology. 42:195-205. 2013. 
 
15. Coppo, M.J., C.A. Hartley, and J.M. Devlin. Immune responses to infectious 
laryngotracheitis virus. Developmental and Comparative Immunology. 41:454-462. 2013. 
 
15 
 
16. Guy, J.S., H.J. Barnes, and L. Smith. Increased virulence of modified-live 
infectious laryngotracheitis vaccine virus following bird-to-bird passage. Avian Diseases. 
35:348-355. 1991. 
 
17. Hughes, C.S., R.M. Gaskell, R.C. Jones, J.M. Bradbury, and F.T. Jordan. Effects 
of certain stress factors on the re-excretion of infectious laryngotracheitis virus from 
latently infected carrier birds. Research in Veterinary Science. 46:274-276. 1989. 
 
18. Hughes, C.S., R.C. Jones, R.M. Gaskell, F.T. Jordan, and J.M. Bradbury. 
Demonstration in live chickens of the carrier state in infectious laryngotracheitis. 
Research in Veterinary Science. 42:407-410. 1987. 
 
19. Hughes, C.S., R.A. Williams, R.M. Gaskell, F.T. Jordan, J.M. Bradbury, M. 
Bennett, and R.C. Jones. Latency and reactivation of infectious laryngotracheitis vaccine 
virus. Archives of Virology. 121:213-218. 1991. 
 
20. TAHC. Infectious Laryngotracheitis (ILT). Texas. 
http://www.tahc.state.tx.us/news/brochures/TAHCBrochure_ILT.pdf. 2013. June 16, 
2015. 
 
21. Veits, J., T.C. Mettenleiter, and W. Fuchs. Five unique open reading frames of 
infectious laryngotracheitis virus are expressed during infection but are dispensable for 
virus replication in cell culture. The Journal of General Virology. 84:1415-1425. 2003. 
 
22. Giambrone, J.J., O. Fagbohun, and K.S. Macklin. Management practices to 
reduce infectious laryngotracheitis virus in poultry litter. J Appl Poult Res. 17:64-68. 
2008. 
 
23. Smith, J.A. Update on laryngotracheitis epidemiology and control methods. The 
Poultry Site. 2008. http://www.thepoultrysite.com/articles/1119/update-on-
laryngotracheitis-epidemiology-and-control-methods/. June 16, 2015. 
 
24. Gingerich, E., and D.K. Carver. Infectious Laryngotracheitis Virus (ILT) Facts. 
Pennsylvania. 2006. http://agriculture.state.pa.us. June 16, 2015. 
 
25. Zhao, W., S. Spatz, Z. Zhang, G. Wen, M. Garcia, L. Zsak, and Q. Yu. Newcastle 
disease virus (NDV) recombinants expressing infectious laryngotracheitis virus (ILTV) 
glycoproteins gB and gD protect chickens against ILTV and NDV challenges. Journal of 
Virology. 88:8397-8406. 2014. 
 
26. Johnson, D.I., A. Vagnozzi, F. Dorea, S.M. Riblet, A. Mundt, G. Zavala, and M. 
Garcia. Protection against infectious laryngotracheitis by in ovo vaccination with 
commercially available viral vector recombinant vaccines. Avian Diseases. 54:1251-
1259. 2010. 
 
16 
 
27. Tong, G.Z., S.J. Zhang, L. Wang, H.J. Qiu, Y.F. Wang, and M. Wang. Protection 
of chickens from infectious laryngotracheitis with a recombinant fowlpox virus  
expressing glycoprotein B of infectious laryngotracheitis virus. Avian Pathology. 30:143-
148. 2001. 
 
28. Sun, Z., and M. Zhang. Effect of the infectious laryngotracheitis virus (ILTV) 
glycoprotein G on virus attachment, penetration, growth curve and direct cell-to-cell 
spread. Science in China. Series C, Life sciences / Chinese Academy of Sciences. 
48:487-494. 2005. 
 
29. Devlin, J.M., G.F. Browning, C.A. Hartley, N.C. Kirkpatrick, A. Mahmoudian, 
A.H. Noormohammadi, and J.R. Gilkerson. Glycoprotein G is a virulence factor in 
infectious laryngotracheitis virus. The Journal of General Virology. 87:2839-2847. 2006. 
 
30. Devlin, J.M., G.F. Browning, and J.R. Gilkerson. A glycoprotein I- and 
glycoprotein E-deficient mutant of infectious laryngotracheitis virus exhibits impaired 
cell-to-cell spread in cultured cells. Archives of Virology. 151:1281-1289. 2006. 
 
31. Chen, H.Y., L. Zhao, Z.Y. Wei, B.A. Cui, Z.Y. Wang, X.S. Li, P.A. Xia, and J.P. 
Liu. Enhancement of the immunogenicity of an infectious laryngotracheitis virus DNA 
vaccine by a bicistronic plasmid encoding glycoprotein B and interleukin-18. Antiviral 
Research. 87:235-241. 2010. 
 
32. Mundt, A., E. Mundt, R.J. Hogan, and M. Garcia. Glycoprotein J of infectious 
laryngotracheitis virus is required for efficient egress of infectious virions from cells. The 
Journal of General Virology. 92:2586-2589. 2011. 
 
33. Lasher, H. Seven decades of developing poultry biologics in the USA. World 
Poultry. Reed Business Informaiton, Netherlands. pp 34-36. 2004. 
 
34. Virus-Serum-Toxin Act. 21, United States Code. pp 151-159. 
 
35. Espeseth, D.A., and H. Lasher. History of regulatory requirements for poultry 
biologics in the United States, 1970s to 1990s. Avian Diseases. 57:167-171. 2013. 
 
36. Code of Federal Regulation. Title 9, part 113. Washinton, DC: U.S. Government 
Printing Office; 2014. 
 
37. USDA New Biotechnology for Preparation of Animal Biological Products. 
800.68 Veterinary Services Memorandum. USDA, Ames, IA. p 4. 1984. 
 
38. USDA General Licensing Considerations: Biotechnology-derived Veterinary 
Biologics Catergories I, II, and III. 800.205 Veterinary Services Memorandum. USDA, 
Ames, IA. p 6. 2003. 
 
17 
 
39. Code of Federal Regulation. Title 9, part 113, section 328. Fowl Laryngotracheitis 
Vaccine. Washinton, DC: U.S. Government Printing Office; 2014. 
 
40. Fahey, K.J., and J.J. York. The role of mucosal antibody in immunity to infectious 
laryngotracheitis virus in chickens. The Journal of General Virology. 71 ( Pt 10):2401-
2405. 1990. 
 
41. Chen, H.Y., P. Cui, B.A. Cui, H.P. Li, X.Q. Jiao, L.L. Zheng, G. Cheng, and A.J. 
Chao. Immune responses of chickens inoculated with a recombinant fowlpox vaccine 
coexpressing glycoprotein B of infectious laryngotracheitis virus and chicken IL-18. 
FEMS Immunology and Medical Microbiology. 63:289-295. 2011. 
 
42. Chen, H.Y., H.Y. Zhang, X.S. Li, B.A. Cui, S.J. Wang, J.W. Geng, and K. Li. 
Interleukin-18-mediated enhancement of the protective effect of an infectious 
laryngotracheitis virus glycoprotein B plasmid DNA vaccine in chickens. Journal of 
Medical Microbiology. 60:110-116. 2011. 
 
43. Rauw, F., Y. Gardin, V. Palya, T. van den Berg, and B. Lambrecht. The 
combination of attenuated Newcastle disease (ND) vaccine with rHVT-ND vaccine at 1 
day old is more protective against ND virus challenge than when combined with 
inactivated ND vaccine. Avian Pathology.  43:26-36. 2014. 
 
44. Iritani, Y., S. Aoyama, S. Takigami, Y. Hayashi, R. Ogawa, N. Yanagida, S. 
Saeki, and K. Kamogawa. Antibody response to Newcastle disease virus (NDV) of 
recombinant fowlpox virus (FPV) expressing a hemagglutinin-neuraminidase of NDV 
into chickens in the presence of antibody to NDV or FPV. Avian Diseases. 35:659-661. 
1991. 
 
45. Yu, Z., E. Manickan, and B.T. Rouse. Role of interferon-gamma in immunity to 
herpes simplex virus. Journal of Leukocyte Biology. 60:528-532. 1996. 
 
46. Christensen, J.P., R.D. Cardin, K.C. Branum, and P.C. Doherty. CD4(+) T cell-
mediated control of a gamma-herpesvirus in B cell-deficient mice is mediated by IFN-
gamma. PNAS. 96:5135-5140. 1999. 
 
47. Decman, V., P.R. Kinchington, S.A. Harvey, and R.L. Hendricks. Gamma 
interferon can block herpes simplex virus type 1 reactivation from latency, even in the 
presence of late gene expression. Journal of Virology. 79:10339-10347. 2005. 
 
48. Steed, A.L., E.S. Barton, S.A. Tibbetts, D.L. Popkin, M.L. Lutzke, R. Rochford, 
and H.W.t. Virgin. Gamma interferon blocks gammaherpesvirus reactivation from 
latency. Journal of Virology. 80:192-200. 2006. 
 
49. Stewart, C.R., A.L. Keyburn, C. Deffrasnes, and S.M. Tompkins. Potential 
directions for chicken immunology research. Developmental and Comparative 
Immunology. 41:463-468. 2013. 
18 
 
CHAPTER 2.  COMPARISON OF THE PATHOGENICITY OF THE USDA 
CHALLENGE VIRUS STRAIN TO A FIELD STRAIN OF INFECTIOUS 
LARYNGOTRACHEITIS VIRUS. 
A paper published in Biolgicals, July 2015 
Danielle M. Koski, Ann S. Predgen, Darrell W. Trampel, Sandra K. Conrad, Debra R. 
Narwold, Joseph R. Hermann 
Abstract 
Infectious laryngotracheitis virus (ILTV) causes respiratory disease in chickens.  
This alphaherpesvirus infects laryngeal tracheal epithelial cells and causes outbreaks 
culminating in decreases in egg production, respiratory distress in chickens and mortality.  
There are several different vaccines to combat symptoms of the virus, including chicken 
embryo origin, tissue culture origin and recombinant vaccines.  All vaccines licensed for 
use in the U.S. are tested for efficacy and potency according to U.S. federal regulation 
using a vaccine challenge assay involving the use of an ILT challenge virus.  This 
challenge virus is provided to biologics companies by the Center for Veterinary Biologics 
(CVB), United States Department of Agriculture (USDA).  The current USDA challenge 
virus originated from a vaccine strain and has been subjected to multiple passages in 
eggs, and may not represent what is currently circulating in the field.  The objective of 
this study was to evaluate and compare the pathogenicity of USDA’s challenge virus 
strain to the pathogenicity of a recent ILT field isolate.   
Using the challenge virus and various dilutions of the field isolate, clinical signs, 
mortality and pathology were evaluated in chickens.  Results indicate that the field isolate 
at a 1:20 dilution is comparable in pathogenicity to the USDA challenge virus at a 1:4 
dilution, and that the ILTV field isolate is a viable candidate that could be used as a 
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challenge virus when evaluating vaccine efficacy. 
1.  Introduction 
Infectious Laryngotracheitis (ILT) is a respiratory disease of chickens which is 
caused by an alphaherpesvirus and classified as Gallid herpesvirus 1.  Disease 
manifestations include respiratory distress, conjunctivitis, and a decrease in egg 
production and mortality (1, 2).  Infectious laryngotracheitis virus (ILTV) infects 
laryngeal and tracheal epithelial cells causing lesions in the trachea of chickens, which 
can lead to mucous build up, tracheal hemorrhaging, suffocation and death.  Direct 
transmission occurs when naïve birds come in contact with infected birds that are in 
respiratory distress or exhibiting conjunctivitis.  As with many herpesviruses, ILTV can 
become latent in birds that survive infection and be reactivated from latency and 
transmitted to asymptomatic birds (2).  Indirect transmission is caused through inanimate 
objects, including personnel, equipment, and contaminated litter, coming into contact 
with infected flocks and then passing the virus on to naïve flocks.   
Measures to control ILTV transmission in poultry houses include biosecurity and 
vaccination programs (1). Vaccination programs often rely on the use of live virus 
chicken embryo origin (CEO) vaccines, which can revert back to virulence and cause 
disease outbreaks (2, 3).  Risk of reversion to virulence of CEO vaccines has led to 
increased interest in recombinant vaccines (1). Predominantly, ILTV recombinant 
vaccines are fowl pox or herpesvirus of turkeys (HVT) vectored with single or multiple 
glycoprotein inserts (4-6). 
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All ILT vaccines currently licensed in the U.S. are live viral vaccines, whether 
they are CEO, tissue culture origin (TCO) or recombinant. CEO and TCO vaccines are 
attenuated through passage in eggs or in tissue culture.   
Although recombinant ILT vaccines are widely used, they may have limitations in 
providing protective immunity when compared to traditional vaccines (7, 8).  Effective 
protection from ILTV replication in the trachea requires a humoral and cell mediated 
response (9). Traditional CEO and TCO ILT vaccines, are administered via eye drop or 
oral routes (i.e. inoculating drinking water) causing the antigen to come into contact with 
the trachea epithelium. Vaccination triggers a cell mediated response from the immune 
system and prevents replication and latency of field strains of ILTV (7-9).  HVT 
recombinant vaccines are administered via in ovo or subcutaneously at hatch, or fowl pox 
vectored vaccines are delivered via wing web puncture.  Recombinant ILT vaccines may 
not induce a strong cell mediated immune response in the respiratory tract of chickens (4, 
8, 9).  
All ILTV vaccines are evaluated for efficacy and potency using vaccination-
challenge studies in accordance with Title 9, Code of Federal Regulations (9 CFR), Part 
113.328, using a challenge virus provided by the United States Department of 
Agriculture’s (USDA) Center for Veterinary Biologics (CVB) (10).  The present USDA 
ILT challenge virus originated from a 1960’s vaccine isolate and may not be 
representative of currently circulating field strains. If so, vaccine strains that protect 
against the USDA’s challenge virus may not confer sufficient protection against all 
circulating field strains.  The objective of this study was to evaluate and compare the 
21 
 
pathogenicity of USDA’s challenge virus strain to the pathogenicity of a recent ILT field 
isolate. 
2.  Materials and Methods 
This study was conducted in accordance with the Guide for the Care and Use of 
Laboratory Animals and approved by the CVB and National Veterinary Services 
Laboratories (NVSL) Animal Care and Use Committee. 
2.1. Challenge viruses.  The present USDA ILT challenge virus (Lot 07-3) 
originated from a vent brush ILT vaccine from the 1960’s.  A challenge virus was 
produced by diluting the previous USDA ILT challenge virus (Lot 86-3) 1:100 in 
tryptose phosphate broth (TPB) (Media # 10426, NVSL, Ames, Iowa) with penicillin-
streptomycin (minimum 23,040 IU/mL penicillin G potassium salt and 72,000 IU/mL 
streptomycin, Media # 30044, NVSL, Ames, Iowa) used at 2% (2 mL per 100 mL).   
From this dilution, 0.2 mL was inoculated into the allantoic cavity of 11 day old specific 
pathogen free (SPF) embryonated chicken eggs (Charles River Laboratories, Wilmington, 
Massachussetts).  At four days post-inoculation, chorioallantoic membranes (CAMs) 
were harvested and frozen at -70oC. Infected CAMs were thawed and added to an equal 
amount of TPB and ground using a Lourdes grinder and Tenbroeck glass manual tissue 
grinder. After grinding, the homogenate was filtered through 4-5 layers of course gauze.  
Approximately 250 mL of homogenate was collected and then brought to a one liter 
volume using TPB with 2% penicillin-streptomycin and 1.5 mL was placed into glass 
cryules using a Cornwall syringe.  Cryules were sealed using a heat sealer and stored at -
120oC. 
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The field isolate (lot 11-11) used in this study was recovered from tracheas of 
egg-type chickens submitted to Iowa State University’s (ISU) Veterinary Diagnostics 
Laboratory (VDL) (Ames, IA).  ILT was diagnosed in these chickens based upon clinical 
signs and the presence of intranuclear inclusion bodies in tracheal epithelial cells. Laying 
hens in the flock of origin had been previously vaccinated with a recombinant ILT 
vaccine.  The tracheas were acquired from ISU’s VDL by the CVB to potentially make 
new challenge virus because the tracheas were locally available and the flock had been 
previously vaccinated for ILT by a vaccine other than a CEO vaccine. 
Harvested tracheas were ground in 11 mL of 10T antibiotic media (Media # 
10411, NVSL, Ames, Iowa) and centrifuged at 1135 g for 20 minutes at 4oC.  Three 
hundred µl of supernatant were inoculated into 11-day-old SPF embryonated chicken 
eggs (Charles River Laboratories, Wilmington, Massachussetts).   ILT virus was 
propagated on the CAM for three serial passages. After the final passage, CAMs were 
harvested, ground in TPB (Media # 10426, NVSL, Ames, Iowa) with 2% penicillin-
streptomycin (Media # 30044, NVSL, Ames, Iowa), filtered through two layers of course 
gauze, diluted 1:1 in TPB, bottled in glass cryules (Wheaton, Millville, New Jersey) and 
stored at -120oC in a vapor phase liquid nitrogen freezer (ThermoScientific, Asheville, 
North Carolina).   
2.2 Testing for extraneous agents. Both the USDA challenge virus and the ILT 
field isolate were tested for poultry extraneous agents in the standard manner as master 
seed viruses as laid out in the 9CFR or in USDA Veterinary Services (VS) memorandum.  
Extraneous agents tested for included anaerobic and aerobic bacteria (9CFR part 113.27), 
fungus (9CFR part 113.27), mycoplasma (9CFR part 113.28), hemagglutinating viruses 
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(9CFR part 113.34), avian leukosis virus (9CFR part 113.31), reticuloendotheliosis virus 
(VS Memo 800.88), and chicken anemia virus (VS Memo 800.89) (11-17). 
2.3. Virus Titration. Titrations of USDA challenge virus and the field isolate were 
performed in 11 day old specific pathogen free embryonated chicken eggs (Charles River 
Laboratories, Wilmington, Massachusetts).  Ten-fold dilutions (10-1 to 10-6) of the 
challenge virus and field isolate were prepared in TPB and 0.2 ml was inoculated via the 
CAM inoculation route.  Six eggs per dilution were inoculated and after seven days the 
CAMs were scored for typical ILT lesions.  The 50% egg infectious dose (EID50) was 
calculated using the Reed-Muench method (18).  Egg titrations were performed on both 
the USDA challenge virus and field isolate after bottling and freezing, with challenge 
virus having an EID50 of 1 x104.1 and the field isolate having an EID50 of 1 x103.4.   
2.4. Experimental Design. Ninety White Leghorn specific pathogen free chickens 
(Charles River Laboratories, Wilmington, Massachusetts) were randomized into eight 
treatment groups at approximately 7 days of age and housed in separate isolator cages 
(PLAS Labs, East Lansing, Michigan) by treatment group (Table 1).  The negative 
control group and six treatment groups inoculated with the ILT field isolate contained 10 
chickens.  Twenty chickens were inoculated with USDA’s current ILT challenge strain.  
Twenty chickens were used for the USDA challenge virus to give a larger number of 
birds to compare to the field isolate.  Each bird was given a unique leg band to allow for 
clinical signs and pathological tracking by bird.   
Viruses were diluted in TPB, and at 34 days of age, each bird was inoculated 
intratracheally with 0.5 mL of appropriate inoculum based on treatment group (Table 1).  
The scientist performing chicken inoculations was unaware of the virus origin and 
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dilution.  After inoculation, the virus solutions used to make the dilutions were titrated in 
eggs to determine the EID50, with the USDA challenge having a value of 1 x 103.5 and 
field isolate having a value of 1 x 102.8.  From those values, the EID50 was calculated for 
each treatment group for both the field isolate and USDA challenge virus (Table 3). 
2.5. Scoring of Clinical Signs.  After inoculation, birds were observed 
independently, twice daily, by two observers for ten days, and symptoms were scored 
according to criteria modified from previous work (Table 2) (19).  Observers were 
blinded to the identity of each treatment group.  Chickens demonstrating hemorrhaging or 
severe dyspnea were humanely euthanized, necropsied and tracheas were harvested.  On 
day 10, the remaining birds were humanely euthanized, necropsied and tracheas 
harvested.  A 2-4 cm section of upper trachea, approximately 2-3 cm from the larynx and 
a 2-4 cm section of lower trachea approximately 1-2 cm from the syrinx were removed 
and placed in buffered formalin solution.  Tracheas were sent to NVSL for pathological 
scoring by a pathologist who was also blinded to the identity of the treatment groups.   
2.6. Effective Dose. Chickens were classified as positive if they had any of the 
following three characteristics: death, multiple symptoms seen multiple days in a row, or 
multiple clinical signs seen by both observers.  A binomial generalized linear model was 
fit to the data using a logit link function (logistic regression), ln(π/(1-π)) = α + β*(-log10 
dilution) (20).  Maximum likelihood estimates were used in estimating the log10 effective 
dose 80 (ED80) as ln (4) – α/β, where ln represents the natural logarithm.  The results 
were back-transformed and presented as the ED80 (20). 
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2.7. Histological sample processing. Transverse sections of trachea were fixed in 
neutral buffered formalin, processed and embedded in paraffin, sectioned to 3 µm 
thickness, mounted on glass slides, and stained with hematoxylin and eosin. 
2.8. Histopathological scoring. Tracheal lesions were scored using a scoring 
system (Table 2) modified from a previous work (21).   In the present study, tracheal 
lesions reflect lesions at the time of death, whether death occurred naturally, at the 
humane endpoint, or at the end of the study.   Scoring criteria reflect not only the 
progression of acute inflammatory changes, but also takes into consideration more 
chronic regenerative changes seen in birds that have been known to recover from 
infection with the virus. Lesion severity was based on loss of mucosal integrity, so that 
lesions demonstrating sloughing and ulceration were given higher scores than lesions in 
which the mucosa was covered by a thickened, but intact, regenerating epithelium (Table 
2).  A bird was considered positive with a tracheal lesion score of 2 or higher.  Tracheal 
lesion scores of 4 or 5 were considered severe. 
3.  Results 
3.1. Pathogenicity.  Clinical signs observed included conjunctivitis, mild dyspnea, 
severe dyspnea, and hemorrhaging from the oropharyngeal cavity and nostrils.  Most 
signs were observed at 4-6 days post-inoculation, except for conjunctivitis, which was 
observed 5-10 days post-inoculation.  Several birds from virus inoculated groups were 
able to recover from dyspnea, depression and conjunctivitis.   
Death or euthanasia due to severe symptoms occurred in most chickens at 4 to 5 
days post-inoculation.  This is similar to results previously reported by researchers using 
other strains of ILTV (19, 21). The number of birds showing clinical signs, those 
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euthanized or chickens that died, and the percentage of positive birds in each treatment 
group are summarized in Table 3. 
All dilutions from both the USDA challenge virus and the field isolate had at least 
one bird either die or show severe enough symptoms to be euthanized.  At the dilution of 
1:4 (EID50 titer 1 x 102.6), the present USDA challenge virus produced 85% positive 
birds.  This was slightly better than the 80% positive rate caused by the field isolate at 
dilutions of 1:4, 1:10 and 1:50 (EID50 of 1 x 101.9, 1 x 101.5, and 1 x 100.8).  Field isolate 
dilutions of 1:20, 1:100, and 1:250 produced positive rates of 90%, 50%, and 40%, 
respectively. The ED80 of the field isolate was estimated as 14.4 (95% CI: 3.3, 61.6).   
The present USDA challenge virus had a mortality rate of 35%.  Similar mortality 
rates were seen for the field isolate at dilutions of 1:4, 1:20, and 1:50, which produced 
mortality rates of 30%, 40%, and 30%, respectively.  
3.2. Tracheal Lesion Scores.  Control birds had normal to slightly hyperplastic 
tracheal mucosa (Fig. 1a). Infected birds demonstrated a variety of lesions ranging from 
slightly hyperplastic through epithelial syncytia formation and sloughing to complete 
ulceration with a hemorrhagic and cellular exudate (Fig. 1b-1f).  Occasional birds had 
intact, occasionally cystic, thickened epithelium interpreted as regeneration (Fig. 1d).   
Upper and lower tracheal lesion scores for each experiment chicken, the 
percentage of birds in each group with positive lesions and the percentage of birds in 
each group with severe lesions is summarized in Table 4.  The USDA challenge virus at a 
1:4 dilution (EID50 of 1 x 102.6) produced upper tracheal lesions in 95% of chickens and 
in 35% of these birds lesions were severe.  In the lower trachea, the USDA challenge 
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virus caused lesions in 85% of inoculated chickens and in 35% of the birds lesions were 
severe. 
Field isolate dilutions of 1:20, 1:50, 1:100, and 1:250 produced severe lesions in 
the upper trachea in 40%, 50%, 20% and 20% of the birds, respectively.  For both the 
1:20 dilution (EID50 of 1 x 101.2) and 1:100 dilution (EID50 of 1 x 100.5) 100% of the birds 
had positive tracheal lesion scores in the upper trachea.  The dilution resulting in the 
highest percentage of severe lesions in the upper trachea, at 50%, was the 1:50 dilution 
(EID50 of 1 x 100.8) of the field isolate.  Field isolate dilutions of 1:20, 1:50, 1:100, and 
1:250 produced severe lesions in the lower trachea in 30%, 50%, 20%, and 20%, 
respectively.  The 1:50 dilution of the field isolate also had 90% positive upper tracheas, 
as did dilutions 1:4, 1:10, and 1:50 (EID50 of 1 x 101.9, 1 x 101.5, and 1 x 100.8). 
In the lower trachea 50% of birds inoculated with the 1:50 dilution had severe 
lesions; however the number of positives was lower, at 80%, when compared with the 
upper trachea lesion scores.  The dilutions of the field isolate at 1:10 and 1:100 (EID50 of 
1 x 101.5 and 1 x 100.5) also had a similar decrease in the number of positives, to 80%, for 
the lower trachea.  The 1:4 and 1:20 dilutions (EID50 titers of 1 x 101.9 and 1 x 101.2) of 
the field isolate had decreases in lesion scores to70% positive for the lower trachea. 
4.  Discussion 
According to 9 CFR 113.328 regulations regarding ILT vaccine testing, at least 
80% of the non-vaccinated birds must show clinical signs and/or death for the challenge 
study to be valid (10).  Infectivity studies conducted in 2007 using birds that had been 
inoculated with the USDA challenge virus lot 07-3 showed 90% of chickens symptomatic 
for ILT at a 1:10 dilution in 2007.  In 2009, a biologics company reported to the CVB 
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that the USDA challenge virus was not causing clinical signs and/or mortality in 80% of 
birds. This observation was confirmed by further bird testing by CVB using a 1:10 
dilution of challenge virus.  The recommendation for using the USDA challenge virus 
was changed to a dilution of 1:4 (EID50 of 1 x 102.6).  The apparent reduction in virulence 
of the USDA’s challenge in chickens initiated the search for a new challenge virus.   
This study indicates the challenge virus presently used by the USDA will still 
cause clinical signs and/or death in over 80% of birds at the 1:4 dilution.  The field isolate 
virus performed to regulatory standards at all dilutions except 1:100 (EID50 of 1 x 100.5) 
and 1:250 (EID50 of 1 x 100.1).  Although the field isolate was prepared slightly 
differently than the USDA challenge, the ILT field isolate caused infection at less 
concentrated dilutions and lower EID50 titers than the current USDA challenge virus.  
The ED80 estimate corroborates using the less concentrated dilution of the ILT field 
isolate. 
Not all birds that had positive trachea scores exhibited clinical signs or mortality.  
This is not unexpected due to the ability of ILT virus to replicate in the trachea without 
exhibiting clinical signs (4).  Surprisingly the ILT field isolate produced upper tracheal 
lesions in 100% of birds at a 1:100 dilution (EID50 of 1 x 100.5) and 80% of birds at a 
1:250 dilution (EID50 of 1 x 100.1).  The percent of birds with positive lower trachea 
scores for the 1:100 and 1:250 dilutions were 80%.  At that same 1:250 dilution, only 
40% of birds were positive based on clinical signs and mortality, indicating that the ILT 
field virus infects the trachea without producing clinical signs or mortality.   
All of the ILT vaccines currently licensed in the U.S. have label claims for the 
“prevention of laryngotracheitis”, not for “the prevention of infection” (22).  The ILT 
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challenge study, as codified, is designed for a vaccine to receive the “prevention of 
disease” claim by basing protection on prevention of clinical signs.  Several studies 
indicate that chickens vaccinated with recombinant ILT vaccines may be asymptomatic 
while challenge or field strain ILT viruses replicate in the trachea (4, 7, 8).  Our study 
supports this, in the fact that we had several birds that were asymptomatic, yet still had 
tracheal lesions for ILT. 
Having a field isolate as vaccine challenge virus would benefit vaccine challenge 
studies by better replicating what chickens will need vaccine protection from in the field.  
Also, a new ILT challenge virus that is representative of current field strains is clearly 
needed in light of the recent ILT outbreaks that have occurred in vaccinated flocks.  The 
ILT field isolate virus used for this study not only produced clinical signs and tracheal 
lesions similar to those seen with the USDA challenge virus, it could be diluted further 
then the USDA challenge virus to achieve the same results.  Based on tracheal scores, 
severity of clinical signs and mortality, and the ED80, the optimal dose for the field isolate 
appears to be a 0.5 ml intratracheal inoculation between dilutions 1:10 and 1:20 (EID50 of 
1 x 101.5 and 1 x 101.2).  All of the information garnered from this work indicates that the 
field isolate is a viable candidate for use in vaccination challenge studies. 
 
Note - D. Koski’s role in journal article and research: First author on journal article.  
Prepared research proposal and submitted to supervisor for approval.  Performed 
inoculation of chickens.  Observed chickens twice daily for ten days.  Euthanized 
chickens and collected all tracheas.  Coordinated sample submission to NVSL’s 
pathology laboratory.  Worked with CVB Statistics section to analyze data. 
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Symptom Score Definition 
Dyspnea 
0 Normal Breathing 
1 Mild, open mouth breathing 
2 Gasping with extended neck 
Conjunctiva 
0 Normal 
1 Swollen and/or partially closed eyes 
2 Eyes completely swollen shut 
Depression 
0 Normal 
1 Mildly depressed, lethargic, will move when startled but not quickly 
2 
Severely depressed, not willing to move, or 
will only move for a short time when 
startled 
Hemorrhage 0 
No presence of blood on beak, head or 
chest 
2 Presence of blood on beak, head or chest 
Mortality (Death) 0 Alive 2 Dead 
 
Table 1: Scoring of clinical sign severity.  Modified from Oldoni et al., 2009. 
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Score Histology 
0 
Normal. Epithelium consists of thin pseudostratified columnar epithelium. 
Mucous glands normal. 
1 
Minimal changes. Normal to slightly thickened epithelium with minimal to 
mild goblet cell or epithelial cell proliferation; minimal to moderate 
infiltration of lymphocytes; heterophils rare.  No syncytia or cells with intra-
nuclear inclusion bodies present.  
2 
Mild changes. Mucosa thickened because of mild to moderate cell infiltration 
and/or epithelium essentially normal except for foci of syncytia with 
intranuclear inclusion bodies. Mucosa may contain groups of epithelial cells 
that have clustered nuclei or are separating from the underlying mucosa. 
Mucosa may be lined by attenuated epithelium with minimal inflammation 
and/or decreased goblet cells. Mucosa may be lined by proliferative layers of 
nonciliated epithelium which contain cyst-like structures. Hyperemia is often 
present. 
3 
Moderate changes. Mucosa thickened because of moderate to marked cell 
infiltration. Numerous syncytia with intranuclear inclusion bodies. Patches of 
affected epithelium often separating from, or, less commonly, sloughed from 
lamina propria. Mucosal surface well covered by normal or affected 
epithelium. Mucous glands reduced. Marked hyperemia, cuffs of mono-
nuclear cells around vessels outside mucosa. 
4 
Severe changes. Mucosa thickened because of edema, proteinaceous fluid, 
cellular exudate, or adherent fibrinohemorrhagic to cellular pseudomembrane 
on the surface. Normal epithelium absent, mucosal surface covered by a thin 
layer of basal cells. Syncytia with inclusion bodies sometimes present. 
5 
Very severe changes. Same as 4, except mucosa has no residual epithelium 
and syncytia with inclusion bodies rarely found. 
 
Table 2: Criteria for histopathological scoring of tracheas. Modified from Oldoni et 
al., 2009. 
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Table 3: Summary of morbidity, mortality and positive percentage of chickens in 
treatment groups. 
 
 
Table 4: Summary of upper and lower trachea pathology scores.  Severe tracheal 
lesions are those with scores 4 or 5.  Positive tracheas are those with scores of 2 or 
higher. 
 
 
 
 
 
 
Treatment Dilution Dose (EID50) 
Classification % 
Positive Negative Morbidity Mortality 
TPB  Negative NA 10 0 0 0 
Challenge Virus  1:4 1 x 102.6 3 10 7 85 
Field Isolate  1:4 1 x 101.9 2 5 3 80 
Field Isolate 1:10 1 x 101.5 2 7 1 80 
Field Isolate 1:20 1 x 101.2 1 6 3 90 
Field Isolate 1:50 1 x 100.8 2 4 4 80 
Field Isolate 1:100 1 x 100.5 5 3 2 50 
Field Isolate 1:250 1 x 100.1 6 3 1 40 
Treatment Dilution 
% Severe 
Lesions 
Upper 
Trachea 
% Positive 
Upper 
Trachea 
% Severe 
Lesions 
Lower 
Trachea 
% Positive 
Lower 
Trachea 
TPB  Negative 0 0 0 0 
Challenge Virus  1:4 35 95 35 85 
Field Isolate 1:4 40 90 30 70 
Field Isolate 1:10 20 90 20 80 
Field Isolate 1:20 40 100 30 70 
Field Isolate 1:50 50 90 50 80 
Field Isolate 1:100 20 100 20 80 
Field Isolate 1:250 20 80 20 80 
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Figure 1.  Representative microscopic tracheal lesions and scores in ILTV infected 
chickens and non-infected controls.  1a:  Normal thin pseudostratified columnar 
epithelium; score 0.  1b:  Mild epithelial and goblet cell hyperplasia and 
hypertrophy; score 1.  1c:  Epithelium containing clusters of nuclei separating from 
the mucosa; score 2.  1d:  Proliferative epithelium forming cyst-like structures 
during regeneration; score 2.  1e: Mucosa thickened because of moderate to marked 
inflammatory cell infiltration; numerous syncytia with intranuclear inclusion 
bodies; score 3.  1f:  Incomplete thin basal covering; score 4.  1g:  Ulcerated mucosa; 
score 5. 
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CHAPTER 3. DISCUSSION: THE COMPLEXITY OF CONTROLLING 
INFECTIOUS LARYNGOTRACHEITIS DISEASE 
 
General Conclusions: 
 
In 1996, ILT was listed as a reportable disease in at least 16 States (1).  In 2010, 
1.8 % of breeder chicken farms in the United States reported ILT disease (2).  The only 
respiratory disease reported with more prevalence on those breeder farms in 2010 was 
Mycoplasma synoviae (2).  In 2011, in the Delmarva region of Delaware, Virginia and 
Maryland, 87 farms had outbreaks of ILT (3).   
ILT prevention is an important, but complex problem for the poultry industry.  
Live, attenuated vaccines can revert to virulence (4-6).  Through normal farm procedures, 
chickens shedding live vaccine can infect naïve chickens (7).  Recombinant vaccines 
expressing one or two glycoproteins of ILTV in a herpesvirus of turkeys or fowl pox 
vector do not revert to virulence, but allow wild type virus to infect, which can lead to 
outbreaks at a later date (8, 9). 
Traditional CEO ILT vaccines are often composed of genetic subpopulations 
known as quasispecies (10).  This is important in relation to the USDA ILT challenge 
virus which derived from a vaccine strain and has been maintained by passage in eggs.  
The USDA ILT challenge virus used to test vaccine efficacy was recently found to have 
become attenuated, requiring increased inoculation concentration to achieve virulence 
(11).  Genetic variation may have allowed attenuation of the challenge virus after serial 
passage in embryonated eggs. 
Environmental pressures can change the population structure of a herpes virus 
quasispecies.  Herpes Simplex Virus type-1 (HSV-1) was found to have genetically 
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variable populations in intra-ocular fluid of patients with herpes virus infection in the eye 
(12).  The populations were also patient diverse and dependent, meaning each patient had 
a different quasispecies population.  HSV-1 is often treated with the antiviral drug 
acyclovir (ACV) (12).  However, some strains of HSV-1 are resistant to ACV.  It is 
suspected that ACV use shifts the viral population in patients toward ACV resistance 
(12). 
A similar situation has been shown to exist in Marek’s Disease Virus (MDV) and 
the attenuation of virus by cell passage.  By full genomic sequencing, it was determined 
that MDV undergoes genetic changes during passage in cell culture, including gene 
deletions in virulence factors as passage in cell culture increased (13).  Between passes 
30 and 40, the virus lost its ability to cause paralysis, and after pass 80, the virus could no 
longer cause neoplastic lesions in nerves (13). However, there was always genetic 
variation in the population, and the genetic changes were never in 100% of the population 
(13).  This could mean that upon passage in chickens, genetic variants of an avirulent 
population may revert to virulence.   
Another study using bacterial chromosomes to clone very virulent MDV 
examined the role of quasispecies in virulence (14).  The very virulent field isolate used 
in the cloning experiments caused cytolytic disease in over 90% of infected birds (14).  
The clones of the very virulent strain could only cause the same percentage of disease in 
birds if inoculated together.  None of the individual clones could cause the same level of 
disease, and one clone did not cause any disease symptoms.  Virulence appears to be 
dependent on genetic variation of the quasispecies (14). 
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The idea of quasispecies in herpes viruses resonates in the context of the 
challenges of controlling ILT.  If the CEO vaccines, as indicated in research, are 
composed of a mixed population of virus, back passage through chickens could 
selectively increase the virulent genetic variants.  The recombinant vaccines allow ILTV 
replication in-vivo, which in turn may allow the amplification of virulent quasispiecies.  
Alternatively, replication may increase genetic variation from replication, thus increasing 
virulence. 
Quasispecies may also factor into challenge virus selection.  For vaccine 
manufacturers to produce effective against ILTV, they need a challenge virus 
representative of field strains that chicken flocks may encounter.  A recently isolated, 
virulent field strain may be an appropriate challenge virus (11).  Genetic analysis of the 
field isolate could determine whether it exists as a quasispecies.   
It may be wise to have a quasispecies challenge virus instead of a purified virus 
strain.  Based on MDV research, the genetic variation of quasispecies may be what 
chickens encounter as virulent field strains.  Further research on isolates from ILT 
outbreaks should determine whether quasispecies play a role in ILTV virulence. 
Outside of biosecurity measures, vaccination is the most used control measure for 
ILT prevention, yet itself is a contributing factor in the epidemiology of the disease. 
Control of ILT in poultry flocks will require increased understanding of ILTV biology 
and poultry immunology.  A better way to control the complex problem of ILT is 
possible, but it will involve a multi-faceted approach of incorporating research across the 
herpesvirus family, educating producers, investigating new technologies, and working 
with biologics producers and regulators. 
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